The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Open accessAbstract
Many genetic liver diseases in newborns cause repeated, often lethal, metabolic crises. Gene therapy using nonintegrating viruses such as adeno-associated virus (AAV) is not optimal in this setting because the nonintegrating genome is lost as developing hepatocytes proliferate. We reasoned that newborn liver may be an ideal setting for AAV-mediated gene correction using CRISPR-Cas9. Here we intravenously infuse two AAVs, one expressing Cas9 and the other expressing a guide RNA and the donor DNA, into newborn mice with a partial deficiency in the urea cycle disorder enzyme, ornithine transcarbamylase (OTC). This resulted in reversion of the mutation in 10% (6.7-20.1%) of hepatocytes and increased survival in mice challenged with a high-protein diet, which exacerbates disease. Gene correction in adult OTC-deficient mice was lower and accompanied by larger deletions that ablated residual expression from the endogenous OTC gene, leading to diminished protein tolerance and lethal hyperammonemia on a chow diet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result, in applications calling for corrective gene insertion, a second AAV vector encoding the sgRNA and/or a template sequence for homologydirected DNA repair must be used, reducing efficiency due to the need for cells to acquire both AAV vectors at once 59,60 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“Currently, researchers most frequently employ a dual AAV system for CRISPR-mediated gene correction: one AAV expresses Cas9 while the other expresses the sgRNA and donor template DNA [24].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [24]
In the citing paper
“Furthermore, there was an increase in survival of mice with a high-protein diet, a stressor which exacerbates this in-born error of metabolism.”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [24]
In the citing paper
“After AAV delivery, these mice experienced a reversion of the mutation in 10% of their hepatocytes.”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 1×
“More extensive characterization of these potential toxicities is necessary before clinical translation can be considered 24,25 , although, in animals treated as newborns, we could not detect indels of likely off-target sites at the level of sensitivity achieved by deep sequencing.”
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624 · cited 1×
“We developed a strategy using a dual-AAV system based on AAV8, which has high liver tropism to correct the point mutation in newborn spf ash mice using Cas9 enzyme from Staphylococcus aureus (SaCas9) 11–13 .”
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“Here, we leveraged our experience with liver-directed gene replacement therapy with highly hepatotropic AAV vectors 22 to move closer to realizing these goals in a model of liver metabolic disease.”
Self-citationGenome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345 · cited 1×
“Cas9 could also elicit pathologic immune responses 16 , as has been observed in gene replacement therapies in which the transgene is a foreign protein.”
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M. W., Alvira, M. R., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 335
Self-citation
Research works printed but not linked: 1
- Lichter-Konecki, U., Caldovic, L., Morizono, H. & Simpson, K. Ornithine transcarbamylase deficiency (1993–2013). in GeneReviews (eds. Pagon, R.A. et al.) http://www.ncbi.nlm.nih.gov/books/NBK154378/ (29 August 2013).
Cited by
Sorted by citations
Items 401–500 of 564
Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency
Fry, L. E., Peddle, C. F., Stevanovic, M., Barnard, A. R., McClements, M. E., & MacLaren, R. E. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0021 · Cited by 10
Ghosh, D., Kumar, A., & Sinha, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820595-2.00006-0 · Cited by 8
Engineered hypercompact Fanzor-ωRNA system with enhanced genome editing activity
Zhao, G., Liu, Y., Zhang, G., Wang, J., Zou, Z., Wang, J., Xu, S., Han, D., Xu, Z., Chen, Z., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.09.031 · Cited by 6
Esmaeili, Y., Farazin, A., Rahimmanesh, I., & Bigham, A. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671540-00170 · Cited by 7
Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications
Sharrar, A. M., Meacham, Z. A., Staples-Ager, J., de Tacca, L. A., Rabuka, D., Collingwood, T. N., & Schelle, M. W. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0010 · Cited by 8
“Split-ting the genetic cargo into multiple vectors or using minimal promoters with the smaller Cas nucleases is an imperfect solution to this problem and requires signi fi cant tradeoffs in AAV packaging, genetic stability, payload expression, and drug development.”
Gene editing in liver diseases
Torella, L., Santana‐Gonzalez, N., Zabaleta, N., & González‐Aseguinolaza, G. (2024) · FEBS Letters · doi:10.1002/1873-3468.14989 · Cited by 7
“Proof-of-concept studies have also explored HDR-based approaches for diseases such as OTCD [90], Hemophilia B [91], and PKU [92].”
Gene therapy: Myth or reality?
Fischer, A. (2016) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2016.04.011 · Cited by 10
“Proofs of principles of success have been achieved in cell lines [30] and animal models of inherited diseases, such as SCID X1 tyrosinemia [31] or urea cycle deficiency [32].”
Genome editing in the human liver: Progress and translational considerations
Ginn, S. L., Christina, S., & Alexander, I. E. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.030 · Cited by 7
Potentials of CRISPR in liver research and therapy
Loesch, R., Desbois‐Mouthon, C., & Colnot, S. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.05.001 · Cited by 6
Cavino, K., Sung, B., Su, Q., Na, E., Kim, J., Cheng, X., Gromada, J., & Okamoto, H. (2020) · Endocrinology · doi:10.1210/endocr/bqaa211 · Cited by 8
Modulating Cas9 activity for precision gene editing
Uslu, M., Si̇yah, P., Harvey, A. J., & Kocabaş, F. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.015 · Cited by 7
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Deborah, R., Cavedon, A., Siddiqui, S., Rice, L., Finn, P. F., et al. (2024) · Cells · doi:10.3390/cells13231979 · Cited by 6
Bortolussi, G., Iaconcig, A., Canarutto, G., Porro, F., Ferrucci, F., Galletta, C., Díaz-Muñoz, C., Rawat, V., Caneva, A. D., Olajide, O. J., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101161 · Cited by 7
“44 While the AAV doses we used here were similar to those used by Yang et al., 44 the differences may be associated with the in vivo targeting ef fi cacy of the sgRNA.”
MethodTsuruya, K., Yokoyama, K., Mishima, Y., Ida, K., Araki, T., Ieda, S., Ohtsuka, M., Inagaki, Y., Honda, A., Kagawa, T., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100616 · Cited by 6
Ban, Q., Lee, J., Shi, Z., Lu, D., Qiao, L., Yang, P., Li, X., Cheng, H., Zhang, M., Hou, J., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101659 · Cited by 6
Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective
Ilahibaks, N. F., Hulsbos, M. J., Lei, Z., Vader, P., & Sluijter, J. P. G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_20 · Cited by 7
Recent Advances in Therapeutic Genome Editing in China
Yang, Y., Wang, Q., Li, Q., Men, K., He, Z., Deng, H., Ji, W., & Wei, Y. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.210 · Cited by 6
“42 The results demonstrated that liver OTC enzyme activity was recovered by clonal expansion in the growing liver.”
Self-citationGene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 6
Engineering precision therapies: lessons and motivations from the clinic
Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 6
Movement Disorders and Inherited Metabolic Disorders
(2020) · Cambridge University Press eBooks · doi:10.1017/9781108556767 · Cited by 6
Long-lasting Analgesia via Targeted in vivo Epigenetic Repression of Nav1.7Preprint
Moreno, A. M., Catroli, G. F., Alemán, F., Pla, A., Woller, S. A., Hu, M. Y., Yaksh, T. L., & Mali, P. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/711812 · Cited by 6
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
“Another approach involves the use of dual AAV systems that independently express Cas proteins and gRNAs using two distinct vectors (Yang et al., 2016).”
Viral delivery of genome-modifying proteins for cellular reprogramming
Mikkelsen, J. G. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.005 · Cited by 6
Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There?
Agarwal, N., Popovic, B., Martucci, N. J., Fraunhoffer, N. A., & Soto–Gutiérrez, A. (2018) · Gene Expression · doi:10.3727/105221618x15350366478989 · Cited by 5
Prenatal Gene Therapy for Metabolic Disorders
Coons, B. E., & Peranteau, W. H. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000662 · Cited by 5
Antibody-mediated delivery of CRISPR-Cas9 ribonucleoproteins in human cells
Ubiparipovic, S., Christ, D., & Rouet, R. (2022) · Protein Engineering Design and Selection · doi:10.1093/protein/gzac011 · Cited by 5
Karami, E., Rostamkhani, F., Abdollahi, M., & Ahmadifard, M. (2025) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2025.100295 · Cited by 7
Gene Therapy in Tyrosinemia: Potential and Pitfalls
Carter, S., & Doyon, Y. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_21 · Cited by 5
In Vivo Exon Replacement in the Mouse Atp7b Gene by the Cas9 System
Liu, L., Cao, J., Chang, Q., Xing, F., Yan, G., Fu, L., Huiyang, W., Ma, Z., Chen, X., Li, Y., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.037 · Cited by 5
“14 The specific mechanism is still unclear.”
InfluentialTherapeutic Gene Editing with CRISPR
Hahn, E., & Hiemenz, M. (2020) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2020.02.008 · Cited by 5
Modern Tools of Genome Engineering and Their Applications
Kaur, R., Singh, A. K., Singh, D. K., & Singh, S. (2023) · Springer eBooks · doi:10.1007/978-981-99-3126-2_9 · Cited by 5
Characterization and Engineering of a Novel Miniature Eubacterium siraeum CRISPR-Cas12f System
Wang, Y., Wang, Y., Tang, N., Wang, Z., Pan, D., & Ji, Q. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00154 · Cited by 5
CRISPR–Cas Gene Editing for Neurological Disease
Simpson, B. P., & Davidson, B. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813997-4.00018-9 · Cited by 5
In vivo RNA targeting of point mutations via suppressor tRNAs and adenosine deaminasesPreprint
Katrekar, D., & Mali, P. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/210278 · Cited by 5
Yu, W., Wang, Y., Li, S., Dai, Y., Li, Y., Zhang, X., Li, B., Qian, S., Zhang, X., & Bi, C. (2025) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2025.03.007 · Cited by 5
“AAV has been successfully utilized to deliver spCas9 for genetic therapies in animal models [27,32].”
Efficacious genome editing in infant mice with glycogen storage disease type Ia
Arnson, B., Ilich, E., von Beck, T., Li, S., Brooks, E. D., Gheorghiu, D., He, G., Weinrub, M., Chan, S. Y., Kang, H., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.181760 · Cited by 5
“The vector design featured a functional G6PC transgene that is effective in GSD Ia due to both early expression from episomal Donor genomes and treating without regard to the pathogenic variants that cause GSD Ia.”
InfluentialMolecular Mechanisms of Breast Cancer Drug Resistance and CRISPR/Cas9 Strategies to Overcome
Hussen, B. M., Ismael, B. S., Abdulla, S. S., Jamal, N. H., Mustafa, S. A., Najmalddin, Z. B., & Rasul, M. F. (2024) · BioMed Target Journal · doi:10.59786/bmtj.221 · Cited by 4
A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo
Li, Y., Chien, S., Huang, R., Herrmann, A., Zhao, Q., Li, P.-C., Zhang, C., Martincuks, A., Santiago, N. L., Zong, K., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.025 · Cited by 7
Self-citationTogashi, T., Baatartsogt, N., Nagao, Y., Kashiwakura, Y., Hayakawa, M., Kamoshita, N., Hiramoto, T., Fujiwara, T., Morishita, E., Nureki, O., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319460 · Cited by 4
“33,48,49 Conventional gene therapy with AAV vectors is not expected to achieve a sustained therapeutic effect in newborns because of the potential dilution of the AAV genome during hepatocyte proliferation.”
Construction of a rAAV-SaCas9 system expressing eGFP and its application to improve muscle mass
Weng, S., Zhao, Y., Yu, C.-H., Wang, X., Xiao, X., Han, L., Zhang, K., Wang, J., & Yang, G. (2021) · Biotechnology Letters · doi:10.1007/s10529-021-03183-1 · Cited by 4
“The smaller sizes of two or more components of a single rAAV system would be necessary to perform genome-editing experiments, including rAAV tissue tropism, and efficient precise targeting and persistent performance of organizations (Zincarelli et al. 2008).”
BackgroundRusso, R. S., & Wilcox, W. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00003-0 · Cited by 4
Therapeutic applications of gene editing in chronic liver diseases: an update
Shin, J. H., Lee, J., Jung, Y. K., Kim, K. S., Jeong, J., & Choi, D. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.6.033 · Cited by 4
Kayesh, M. E. H., Hashem, M. A., Kohara, M., & Tsukiyama–Kohara, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.953218 · Cited by 4
“…are restricted by their limited packaging capacity (Grieger and Samulski, 2005), by using dual AAV vectors or triple AAV vectors, the transfer capacity of AAV can be expanded from 4.7 kb to approximately 9 or 14 kb, respectively (Yang et al., 2016; Bak and Porteus, 2017; Maddalena et al., 2018).”
BackgroundInfluentialIntravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection
Zhen, S., Chen, H., Lu, J., Yang, X., Tuo, X., Chang, S., Tian, Y., & Li, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28552 · Cited by 5
Ex Vivo Enteroids Recapitulate In Vivo Citrulline Production in Mice
Wang, X., Yuan, Y., Didelija, I. C., Mohammad, M. A., & Marini, J. C. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy126 · Cited by 4
“Despite the reduction in hepatic OTC abundance and only 5–15% residual in vitro enzyme activity compared with WT control mice (26, 27), urea production was not different between the mutant and control mice during feed deprivation.”
BackgroundRajesh, A., Havas, A. P., Arnold, R., Lande, K., Evensen, K. G., Li, K. Y., Mamde, S., Yang, Q., Gandhi, A., Miller, K. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.01.668243 · Cited by 4
Ji, Y., Yu, B., Zhang, Y., & Wu, W. (2022) · European Journal of Ophthalmology · doi:10.1177/11206721211049001 · Cited by 3
High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay
Zhen, S. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70415 · Cited by 3
“In addition, down-regulation of tumor ‐ associated antigens (TAAs), also known as tumor antigen escape [14 – 16], and reduced recognition of TAAs by immune cells through alterations in the antigen ‐ processing machinery both play a significant role in the promotion of tumor progression [17].”
Current Treatment Modalities for Urea Cycle Disorders
Mew, N. A., & Lichter‐Konecki, U. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00719-0 · Cited by 3
“Yang et al. [53] intravenously administered two AAV vectors to newborn mice with partial OTC deficiency: one expressing Cas9, and the other expressing both the guide RNA and the donor DNA template to drive homology-directed repair.”
Li, M., Zubair, A., Wdidi, S., & He, S. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70986 · Cited by 4
“This limitation has been addressed by incorporating SpCas9 and sgRNA sequences into separate plasmids [90, 97] shown that the dual-lobed architecture of SpCas9 can be efficiently utilised in the intein-mediated protein splicing mechanism to recombine two AAVs into a seamless, full-length SpCas9.”
Zhai, D., Ni, J., Shao, X., Zhao, W., Chen, Y., Fan, K., Li, J., Shen, Y., Lin, A., Hu, W., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001708 · Cited by 3
Self-citationThe application of CRISPR-Cas9 system in brain diseases
Miao, Y., Li, C., Su, Y., Peng, T., Wang, J., Liu, S., Ma, C., Li, L., & Wang, Y. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2629031 · Cited by 3
Application of synthetic biology in bladder cancer
Ding, M., Lin, J., Qin, C., Wei, P., Tian, J., Lin, T., & Xu, T. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002344 · Cited by 3
“2 kb) was divided into two parts before being packaged into AAV separately.([28,29]) However, these dual AAV systems reduce the delivery efficiency and biological activity of Cas proteins.”
BackgroundTherapeutic Gene Editing in Muscles and Muscle Stem Cells
Tabebordbar, M., Cheng, J. K. W., & Wagers, A. J. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_10 · Cited by 3
“…cell types frommultiple organisms both in vitro (Cho et al. 2013; Cong et al. 2013; DiCarlo et al. 2013; Ding et al. 2013; Friedland et al. 2013; Hwang et al. 2013; Mali et al. 2013; Wu et al. 2016) and in vivo (Ding et al. 2014; Xue et al. 2014; Yin et al. 2014; Ran et al. 2015; Yang et al. 2016).”
BackgroundProspects for Cell-Directed Curative Therapy of Phenylketonuria (PKU)
Harding, C. O. (2019) · Molecular Frontiers Journal · doi:10.1142/s2529732519400145 · Cited by 3
Recent Advances in In Vivo Somatic Cell Gene Modification in Newborn Pups
Nakamura, S., Morohoshi, K., Inada, E., Sato, Y., Watanabe, S., Saitoh, I., & Sato, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015301 · Cited by 3
“It is likely that the findings of Yang et al. (low efficiency of HDR in adult hepatocytes) [118] reflect the low proliferative ability of adult hepatocytes.”
BackgroundMethodInfluentialNovel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation
Yu, C., Stefanson, O., Liu, Y., & Wang, Z. A. (2018) · Journal of Visualized Experiments · doi:10.3791/57649 · Cited by 3
Gene editing based hearing impairment research and therapeutics
Kang, W., Sun, Z., Zhao, X., Wang, X., Tao, Y., & Wu, H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134326 · Cited by 4
Novel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation
Yu, C., Stefanson, O., Liu, Y., & Wang, Z. A. (2018) · Journal of Visualized Experiments · doi:10.3791/57649-v · Cited by 3
Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9Preprint
Agudelo, D., Carter, S., Velimirovic, M., Duringer, A., Levesque, S., Rivest, J.-F., Loehr, J., Mouchiroud, M., Cyr, D., Waters, P. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/321208 · Cited by 3
Treatment of a metabolic liver disease by in vivo prime editing in micePreprint
Böck, D., Rothgangl, T., Villiger, L., Schmidheini, L., Mathis, N., Ioannidi, E. I., Kreutzer, S., Kontarakis, Z., Rimann, N., Grisch‐Chan, H. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.17.456632 · Cited by 3
Recent progress of principal techniques used in the study of Müller glia reprogramming in mice
Yin, Z., Kang, J.-H., Xu, H.-A., Huo, S., & Xu, H.-W. (2024) · Cell Regeneration · doi:10.1186/s13619-024-00211-z · Cited by 2
Genome engineering with Cas9 and AAV repair templates, successes and pitfalls
Birling, M., Hérault, Y., & Pavlovic, G. (2025) · Mammalian Genome · doi:10.1007/s00335-024-10099-4 · Cited by 3
“Initially, rAAV has been used effectively as donor vec - tors for HDR in immune cells in both in vitro and in vivo settings (De Ravin et al. 2017; Dever et al. 2016; DeWitt et al. 2016; Sather et al. 2015; Wang et al. 2015; Yang et al. 2016; Yin et al. 2016).”
Bhadury, R., Athar, M., Mishra, P., Gogoi, C., Sharma, S., & Ghorpade, D. S. (2025) · Cells · doi:10.3390/cells14050372 · Cited by 2
“For example, preclinical studies have demonstrated the efficacy of AAV-delivered cargo in correcting genetic defects in animal models of diseases like muscular dystrophy, hypercholesterolemia, congenital amaurosis, hemophilia, and urea cycle disorders [13–17].”
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 3
The applications and advances of CRISPR-Cas9 in medical research
Lu, X., Sun, H., Xu, Y. J., Xi, Y., & Gu, B. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw036 · Cited by 2
Genome Editing of Pluripotent Stem Cells for Adoptive and Regenerative Cell Therapies
Blassberg, R. A. (2022) · GEN Biotechnology · doi:10.1089/genbio.2021.0010 · Cited by 3
Zhu, J., Qin, T., Wei, L., Chen, F., Ding, Y., Zhang, Q., & Dang, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-4426 · Cited by 3
“used the AAV8-based dual vector method to reverse 10% of the hepatocyte mutations in newborn mice with Cas9-mediated metabolic liver illness (26).”
MethodRecent advances in CRISPR-Cas system for the treatment of genetic hearing loss.
Yin, G., Wang, X., & Sun, Y. (2023) · PubMed Central · Cited by 3
Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
Benyamini, B., Esbin, M. N., Whitney, O. N., Walther, N., & Maurer, A. C. (2023) · Journal of Visualized Experiments · doi:10.3791/65572 · Cited by 2
Venkatraman, S., Tharun, S. S., Pavithra, A., & Amala, R. (2024) · Pharmaceutical science. · doi:10.5772/intechopen.112924 · Cited by 3
李, 大., 刘, 明., 王, 立., & 张, 晓. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00208 · Cited by 1
Gene Editing in Regenerative Medicine
Fang, Y., Chen, X., & Godbey, W. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00042-4 · Cited by 2
Ma, F., Shi, C., Liang, P., Li, S.-T., Gu, X., Xiao, X., & Hu, H. (2019) · PubMed Central · doi:10.7499/j.issn.1008-8830.2019.08.016 · Cited by 2
Biogen and UPenn join forces to commercialize gene therapies
Sheridan, C. (2016) · Nature Biotechnology · doi:10.1038/nbt0816-791 · Cited by 2
Precision Cas9 Genome Editing in vivo with All-in-one, Self-targeting AAV VectorsPreprint
Ibraheim, R., Tai, P. W. L., Mir, A., Javeed, N., Wang, J., Rodríguez, T., Nelson, S. J., Khokhar, E. S., Mintzer, E., Maitland, S. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.09.333997 · Cited by 2
Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integrationPreprint
Chen, X., Niu, X., Liu, Y., Zheng, R., Wang, L., Yang, L., Lu, J., Yin, S., Shao, Y., Yu, W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435908 · Cited by 2
Self-citationSoltaninejad, H., Khoshandam, M., Hamidieh, A. A., & Hosseinkhani, S. (2022) · doi:10.22541/au.165268627.74823408/v1 · Cited by 1
Revolutionizing animal husbandry: Breakthroughs in gene editing delivery systems
Liu, Y., Bai, X., Feng, X., Liu, S., Hu, Y., Chu, H., Zhang, L., Cai, B., & Ma, Y. (2024) · Gene · doi:10.1016/j.gene.2024.149044 · Cited by 1
Saberi, F., Yousefi-Najafabadi, Z., Shams, F., Dehghan, Z., Ahmadi, S., Pilehchi, T., Noori, E., Esmaeelzadeh, Z., Bazgiri, M., Mohammadi, R., et al. (2025) · Current Gene Therapy · doi:10.2174/0115665232345516241119070150 · Cited by 3
Singh, R., Pandey, S., Pandey, A., & Kumar, G. (2025) · CABI biotechnology series. · doi:10.1079/9781800626638.0001 · Cited by 1
Clinical and biochemical footprints of inherited metabolic diseases: Ia. Movement disorders, updated
Peacock, D. J. S. J., Ferreira, C. R., Horvath, G. A., Hoffmann, G. F., Blau, N., & Ebrahimi‐Fakhari, D. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109084 · Cited by 4
Ginn, S., Doroudian, F., Christina, S., Chan, O. P. Y., Lucas, C., Zhu, E.-H., Yang, S. F., Devanapalli, B., Klein, A. H., Scott, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.044 · Cited by 2
Adaptive model-guided protein evolution with sparse data optimizes compact eukaryotic genome editors
Wan, S., Gold, J., Vure, P., Mogilevsky, C. S., Talikoti, A., Chen, T., Gupta, A., Biswas, T., You, Z., Acharya, V., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03272-4 · Cited by 2
Non-invasive control of gene editing in vivo by photoswitchable Cas12f and focused ultrasound
Song, D., Malinao, M. G., Wu, X., Jiang, S., Jiang, D., Westberg, M., Su, Y., Cai, S., Lee, D., Repina, N. A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.09.005 · Cited by 1
Hentzschel, F., Herrmann, A.-K., Mueller, A., & Grimm, D. (2016) · FEBS Letters · doi:10.1002/1873-3468.12187 · Cited by 1
A novel and highly efficient AAV6 mutant
Wang, F., Huang, C., Cao, J., Liu, X., Wang, D., Zhang, C., & Chen, Q. (2017) · Virus Genes · doi:10.1007/s11262-017-1531-2 · Cited by 1
Gene and cell therapy of adrenal pathology: achievements and prospects
Glazova, O., Vorontsova, M. V., Sakr, N., Shevkova, L., Onyanov, N., Kaziakhmedova, S., & Volchkov, P. (2021) · Problems of Endocrinology · doi:10.14341/probl12818 · Cited by 2
Current trends and risks associated with the use of therapies based on genome editing
Анатольевна, Р. О., Melnikova, E. V., & Меркулов, В. А. (2023) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2023-23-3-247-261 · Cited by 2
Ocular Gene Therapy: Literature Review
Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v40.2.5623 · Cited by 1
Gene Editing in Hematopoietic Stem Cells
Liao, J., & Wu, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_11 · Cited by 2
Jin, X., Ye, Q., Wu, X., Su, J., Song, L., Fu, J., Qiuxia, X., Luo, M., Liu, F., Ren, C., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00741 · Cited by 2
“DNA was extracted from liver tissue, and total vector genomes were quantified using TaqMan qPCR, as previously described [30].”
Self-citationEngineering of Human-Induced Pluripotent Stem Cells for Precise Disease Modeling
Lisowski, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90695-9_15 · Cited by 1
Future Therapeutic Approaches for Alagille Syndrome
Andersson, E. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-94571-2_12 · Cited by 1
Therapeutic Applications of CRISPR/Cas9 Technology for Infectious Diseases
Sharma, G., Rehman, S., & Sharma, A. R. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_25 · Cited by 1
Gene Therapy in Liver Disease: Challenges and Outcomes
Premkumar, M., & Singh, V. (2022) · Springer eBooks · doi:10.1007/978-981-16-8845-4_14 · Cited by 1
AAV-mediated CRISPR/Cas gene editing of retinal cells in vivoPreprint
Hung, S. S., Chrysostomou, V., Li, F., Lim, J. K., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/039156 · Cited by 1
“41 With ongoing advances in viral engineering and the development of new serotypes, future research investigating the efficacy of different viral-CRISPR/Cas systems in the retina, is warranted.”
BackgroundNishiguchi, K. M., Fujita, K., Katayama, S., & Nakazawa, T. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/552653 · Cited by 1
Efficient Immune Cell Genome Engineering with Improved CRISPR Editing ToolsPreprint
Chan, W., Gottschalk, R. A., Yao, Y., Pomerantz, J. L., & Germain, R. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.13.947002 · Cited by 1
“Many reported HDR applications relevant to immune cell manipulation 85 involve targeting embryos (24) or newborn mice (25), not mature immune T cells.”
BackgroundAmelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integrationPreprint
Li, D., Chen, X., Niu, X., Liu, Y., Zheng, R., Wang, L., Yang, L., Lu, J., Yin, S., Shao, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-302699/v1 · Cited by 1
Self-citation
Metadata
- Authors
- Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., Batshaw, M. L., & Wilson, J. M.
- Affiliations
- Sichuan University (CN)
- University of Pennsylvania (US)
- Children's National (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Wilson, James M
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2016-02-01
- Volume
- 34
- Issue
- 3
- Pages
- 334-338
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4786489
- OpenAlex
- W2253584908
- Cited by
- 556
- References
- 36
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 36 · 2023: 52 · 2022: 55 · 2021: 61 · 2020: 70 · 2019: 62 · 2018: 72 · 2017: 71 · 2016: 30
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01HD057247)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, CRISPR/Cas9, gene correction, ornithine transcarbamylase deficiency, urea cycle disorders, neonatal mice, liver disease, hyperammonemia, high-protein diet, hepatocytes, gene therapy
- MeSH terms
- Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Ornithine Carbamoyltransferase, Viruses, RNA Editing, Gene Transfer Techniques, Ornithine Carbamoyltransferase Deficiency Disease, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
